Business
Novo Nordisk Shares Rise Despite 2025 Outlook Downgrade Amid Weight-Loss Drug Market Pressures
Shares in Novo Nordisk surged on Wednesday after the Danish pharmaceutical giant posted stronger-than-expected first-quarter earnings, even as it lowered its growth outlook for 2025 due to mounting competition in the weight-loss drug market.
The company, best known for its diabetes and obesity treatments, reported a 20% year-on-year rise in net profit to 38.8 billion Danish kroner (€5.2 billion), with net sales up 18% to 78.1 billion kroner (€10.5 billion). Both figures exceeded analyst expectations, driven by robust demand for obesity and diabetes medications.
Despite the upbeat results, Novo Nordisk cut its full-year guidance. The firm now expects 2025 sales growth of 13–21%, down from its earlier projection, and operating profit growth between 16–24% at constant exchange rates—both lowered by several percentage points.
“We have reduced our full-year outlook due to lower-than-planned branded GLP-1 penetration, which is impacted by the rapid expansion of compounding in the US,” CEO Lars Fruergaard Jørgensen said in a statement. “We are actively focused on preventing unlawful and unsafe compounding and on efforts to expand patient access to our GLP-1 treatments.”
Still, shares rose 4.4% at the opening of European trading, though the stock remains down 26% since the start of the year. In contrast, main U.S. competitor Eli Lilly has seen a more stable stock performance in 2025.
A key pressure point for Novo Nordisk is the U.S. market, where demand for GLP-1-based weight-loss treatments like Wegovy has outpaced supply. Under FDA policy, compounding pharmacies were permitted to produce alternative versions of drugs in short supply, allowing smaller rivals to offer cheaper options. Although the FDA declared shortages over earlier this year, it granted a grace period until May 22 for compounded versions to remain in circulation.
In response, Novo Nordisk slashed Wegovy’s price by more than half on its online platform, NovoCare, mirroring similar price cuts by Eli Lilly.
In its outlook, Novo Nordisk highlighted the continued global rollout of Wegovy, noting there are an estimated one billion people living with obesity worldwide, yet only a fraction are receiving treatment. CFO Karsten Munk Knudsen said he expects Wegovy sales to pick up further in the third quarter.
Meanwhile, the company announced the completion of its REDEFINE 2 trial for its next-generation drug, CagriSema, which showed a 15.7% weight reduction. While the results fell short of the 25% reduction some had hoped for, Novo Nordisk aims to file for regulatory approval early next year.
The company also said it has filed for U.S. approval of a new oral formulation of semaglutide, which could become the first oral GLP-1 drug for obesity treatment.
Despite market headwinds, Novo Nordisk remains optimistic about future growth in a highly competitive but fast-expanding global obesity market.
Business
Global Markets Rise as US–Iran Talks Ease Sentiment, but Oil and Geopolitical Risks Persist
Global financial markets advanced on Friday as investors reacted cautiously to signs of progress in US–Iran negotiations, though ongoing disruption to shipping through the Strait of Hormuz and elevated oil prices kept risk sentiment fragile.
European equities opened higher across the board. The DAX gained 0.64%, supported by a 3.61% rise in Deutsche Post AG shares. France’s CAC 40 climbed 0.65%, led by a 3.43% jump in STMicroelectronics. In London, the FTSE 100 rose 0.38%, with gains in financial stocks including 3i Group, while the Euro Stoxx 50 added 0.88%.
Currency markets were relatively steady, with the euro trading at $1.161 and the British pound at $1.342 in early European trading. Sentiment was also lifted by better-than-expected economic data from Germany, where first-quarter growth came in at 0.4% year on year and consumer confidence improved heading into June, offering cautious optimism for Europe’s largest economy.
Asian markets followed the upward trend. Japan’s Nikkei 225 surged 2.7% to 63,339 after data showed inflation easing to a four-year low of 1.4% in April. Taiwan’s Taiex rose 2.2%, while Hong Kong’s Hang Seng and China’s Shanghai Composite each gained 0.9%. South Korea, Australia, and India also posted modest increases, reflecting broad regional strength.
Wall Street had earlier closed slightly higher. The S&P 500 added 0.2%, the Dow Jones rose 0.6%, and the Nasdaq edged up 0.1%. However, technology stocks showed mixed signals, with Nvidia falling 1.8% despite strong quarterly results, as investors weighed valuations against broader market uncertainty.
Oil markets remained the key source of volatility. Brent crude climbed 2.3% to $104.97 a barrel, while US West Texas Intermediate rose 1.8% to $98.10. Prices remain significantly above pre-conflict levels, driven by continued disruption in the Strait of Hormuz, through which roughly a quarter of global seaborne oil flows pass.
Shipping through the strategic waterway remains constrained, with limited signs of recovery as diplomatic negotiations continue without resolution. Analysts say markets are highly sensitive to developments in talks between Washington and Tehran, with ING commodities strategists noting that optimism exists but uncertainty dominates trading conditions.
Geopolitical tensions also weighed on policy discussions in Washington, where a planned congressional vote on war powers legislation was postponed amid insufficient support.
In bond markets, US Treasury yields eased slightly to 4.57% after earlier spikes driven by inflation concerns linked to energy prices. The movement reflected ongoing caution among investors balancing growth expectations with persistent geopolitical risk.
Corporate earnings added a bright spot in Asia, where Lenovo Group surged more than 20% after reporting stronger-than-expected quarterly revenue of $21.6 billion, driven by robust performance in its PC and smart devices division.
Business
Goldman Sachs tapped to lead SpaceX IPO as Musk eyes record-breaking market debut
Business
Greek Stocks Stage Remarkable Comeback After Years of Financial Turmoil
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
